GE HealthCare and Mayo Clinic Launch MI-BET Study to Personalize Radioligand Therapy in Advanced Prostate Cancer
Key Insights
GE HealthCare and Mayo Clinic announced the MI-BET research collaboration to evaluate whether imaging and biomarker insights can personalize radioligand therapy for advanced prostate cancer (search) patients.
The study challenges the conventional fixed-cycle RLT approach by using StarGuide SPECT/CT and MIM LesionID Pro to track tumor response and guide adaptive treatment decisions.
Mayo Clinic is the first U.S. site to investigate GE HealthCare's next-generation StarGuide GX SPECT/CT technology, which aims to improve tumor assessment precision and reduce scan times.
GE HealthCare and Mayo Clinic have announced the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) research collaboration, a novel theranostics study designed to explore a more personalized approach to radioligand therapy (RLT) for patients with advanced prostate cancer (search). Announced on July 8, 2026, the collaboration stems from the 2023 Strategic Radiology Research Alliance between the two organizations, aimed at transforming the experience of patients and clinicians in the practice of radiology and the delivery of novel therapies.
The MI-BET study directly challenges the conventional paradigm in which patients receiving RLT follow a standardized, preset number of treatment cycles. Instead, the trial will evaluate whether imaging- and biomarker-informed insights can support a more individualized approach, where treatment may be adapted — including a pause in RLT — based on the patient's disease response over time.
"This collaboration is an example of how Mayo Clinic leads in discovery by integrating novel technologies into our practice and accelerating innovation across research and clinical care to advance the future of medicine," said Andrew Danielsen, chief business development officer at Mayo Clinic. "By bringing together complementary expertise and capabilities, we can enable our world-class researchers and physicians to develop new insights, expand treatment possibilities, and ultimately provide the best outcomes for our patients globally."
Imaging and Biomarker-Driven Treatment Adaptation
The MI-BET study will deploy GE HealthCare's StarGuide SPECT/CT technology alongside MIM Software (search)'s MIM LesionID Pro to monitor how tumors respond to treatment throughout the course of therapy. By integrating imaging data with clinical outcomes and blood-based biomarkers, the Mayo Clinic research team aims to explore whether these combined insights can inform treatment decisions and potentially support the development of predictive markers for patient response.
Predictive marker insights could enable researchers and clinicians to anticipate how patients will respond before or early in treatment, further empowering physicians to make adaptive treatment decisions. This approach reflects a growing shift in oncology toward more adaptive, patient-specific care models.
"Personalizing therapy is both a scientific pursuit and an opportunity to expand patient access," said Geoffrey Johnson, M.D., Ph.D., chair of the Radiopharmaceutical Trial Team at Mayo Clinic Comprehensive Cancer Center. "Theranostics, and studies such as MI-BET, give us an important opportunity to rethink how and when we treat cancer. By evaluating response earlier in their treatment, we can generate data to drive approaches that could help reduce unnecessary therapy while expanding access to care for wider populations."
Expanding Access to Theranostic Care
Beyond evaluating treatment duration, the MI-BET study is designed to encourage broad patient participation through outreach, collaboration with community and advocacy organizations, and the use of approaches such as telemedicine that may help reduce barriers to enrollment and engagement. The initiative also seeks to contribute to the broader evolution of theranostics by exploring new imaging biomarkers and data-driven approaches designed to support clinical decision-making.
"Making theranostics truly adaptive and personalized requires strong clinical evidence and a deeper understanding of how patients respond to therapy," said Sergio Calvo, global general manager, Theranostics, at GE HealthCare. "Through our collaboration with Mayo Clinic, we are exploring how imaging and data-driven insights can help inform more individualized treatment decisions, support the broader adoption of these approaches and contribute to the continued growth of precision care in oncology."
Next-Generation SPECT/CT Technology Under Investigation
MI-BET research activities will be based at Mayo Clinic's campus in Rochester, Minnesota, leveraging both organizations' strengths in clinical practice, research, and product development. Notably, Mayo Clinic is the first U.S. site to investigate the benefits that could be achieved with GE HealthCare's next-generation SPECT/CT StarGuide GX technology. This includes exploring the potential for reduction in scan time and increasing precision in tumor assessments. The StarGuide GX system has received CE Mark certification but is not yet approved or cleared by the FDA and is not available for commercial sale in the United States.
Market Context and Strategic Significance
The collaboration reinforces GE HealthCare's growing focus on precision oncology and theranostics, a rapidly evolving area of cancer care. According to data from Precedence Research, the global theranostics market was valued at $10.29 billion in 2025 and is projected to reach approximately $31.38 billion by 2035, expanding at a compound annual growth rate (CAGR) of 11.8%. Market growth is driven by the rising incidence of chronic diseases, the shift toward personalized medicine, and advances in molecular imaging and radiopharmaceuticals.
By leveraging its StarGuide SPECT/CT platform and MIM Software (search)'s advanced imaging capabilities in a high-profile clinical research setting, GE HealthCare stands to strengthen the clinical validation and long-term adoption of its imaging technologies. Positive findings from the MI-BET study could accelerate adoption of the company's molecular imaging solutions across healthcare systems while reinforcing GE HealthCare's role as a strategic partner in data-driven cancer care.